StemCells, Inc. Announces Webcast to Discuss Third Quarter 2013 Financial Results and Business Update

StemCells, Inc. Announces Webcast to Discuss Third Quarter 2013 Financial
Results and Business Update

NEWARK, Calif., Oct. 31, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc.
(Nasdaq:STEM), a leading stem cell company developing and commercializing
novel cell-based therapeutics and tools for use in stem cell-based research
and drug discovery, announced today that it will release financial results for
the third quarter ended September 30, 2013 after the market close on Tuesday,
November 5. In connection with this announcement, StemCells will host a
conference call and webcast to discuss its results and an update on its
business at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) the same day.

Interested parties are invited to listen to the call over the Internet by
accessing the Investors section of the Company's website at
www.stemcellsinc.com. Webcast participants should allot extra time before the
webcast begins to register and, if necessary, download and install audio
software.


Event:   Q3 2013 Financial Results Conference Call / Webcast
        
Date:    Tuesday, November 5, 2013
        
Time:    1:30 PM PT (4:30 PM ET)
        
Live     http://investor.stemcellsinc.com/phoenix.zhtml?c=86230&p=irol-calendar
webcast:


An archived version of the webcast will also be available for replay on the
Company's website beginning approximately two hours following the conclusion
of the live call and continuing for a period of 30 days.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization
of cell-based therapeutics and tools for use in stem cell-based research and
drug discovery. The Company's proprietary HuCNS-SC® cells (purified human
neural stem cells) are currently in development as a potential treatment for a
broad range of central nervous system disorders. In a Phase I clinical trial
in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in
children, the Company has shown preliminary evidence of progressive and
durable donor-derived myelination in all four patients transplanted with
HuCNS-SC cells. The Company is conducting a Phase I/II clinical trial in
chronic spinal cord injury in Switzerland, Canada and the United States, and
has reported positive interim data for the first three patients.The Company
is also conducting a Phase I/II clinical trial in dry age-related macular
degeneration (AMD) in the United States. In addition, the Company is pursuing
preclinical studies in Alzheimer's disease, with support from the California
Institute for Regenerative Medicine (CIRM).  StemCells also markets stem cell
research products, including media and reagents, under the SC Proven®
brand.Further information about StemCells is available at
http://www.stemcellsinc.com.

Apart from statements of historical fact, the text of this press release
constitutes forward-looking statements within the meaning of the U.S.
securities laws, and is subject to the safe harbors created therein.These
forward-looking statements speak only as of the date of this news release. The
Company does not undertake to update any of these forward-looking statements
to reflect events or circumstances that occur after the date hereof. Such
statements reflect management's current views and are based on certain
assumptions that may or may not ultimately prove valid. The Company's actual
results may vary materially from those contemplated in such forward-looking
statements due to risks and uncertainties to which the Company is subject,
including those described under the heading "Risk Factors" in the Company's
Annual Report on Form 10-K for the year ended December 31, 2012 and in its
subsequent reports on Forms 10-Q and 8-K.

CONTACT: Rodney Young
         StemCells, Inc.
         Chief Financial Officer
         (510) 456-4128
        
         Ian Stone
         Russo Partners
         (619) 308-6541

company logo
 
Press spacebar to pause and continue. Press esc to stop.